Cervical cancer screening using the Cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China

Abstract

ObjectivesThe Cervista® high-risk human papillomavirus (HR-HPV) test was evaluated as a primary screening method for cervical cancer in women aged ≥21 years and was compared with different screening and triage combinations.Materials and methodsA nested case–control study within the Fujian provincial Cervical Lesion Screening Cohorts was used to evaluate the Cervista test as the primary cervical screening method in a hospital-based population. Strategy 1 primarily screened using a cytology screen with HR-HPV testing used for triage. Strategy 2 primarily screened using cytology and HR-HPV co-testing. Strategy 3 primarily screened using HR-HPV testing and triaged HPV-positive women based on cytology. Strategy 4 primarily screened using HR-HPV testing and referred A9 pool HPV-positive women to colposcopy directly, whereas non-A9 HPV-positive women were triaged using cytology.ResultsThere were 10,183 women included in this study; 16.49% (1677/10,183) were HR-HPV-positive, 9.52% had abnormal cytology, and 9907 women were normal during followup. A total of 276 women were diagnosed with cervical intraepithelial neoplasia 2 or worse (CIN2+), 197 with CIN3 or worse (CIN3+), and 70 with cervical cancer. Moreover, 10.15% (20/197) women who were CIN3+ were identified as cytology-negative, while 8.63% (17/197) were HR-HPV negative (P>0.05). The cumulative risk rate for HPV–/cytology– was 0.836 (95% CI, 0.424–1.648) in CIN3+ cases. Strategy 4 yielded the highest sensitivity for CIN2+ or CIN3+ and the lowest positive predictive value for CIN2+ or CIN3+ among the four screening strategies.ConclusionThe Cervista HR-HPV test can provide a reliable and sensitive clinical reference for the cervical cancer primary screen.

PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort

“…Until now, only Cobas ® has been approved by FDA as an HPV test for the primary screening of cervical cancer. In another previous cohort study, we confirmed that other assays such as Cervista ® HR-HPV detection could be used as primary screening tests for cervical cancer [ 28 ]. Our previous articles have shown that the PCR-RDB HPV genotyping test can provide a reliable and sensitive clinical reference for HPV detection [ 15 29 ].…”

Clinical validation of the Cervista^® high-risk human papillomavirus test in Chinese women from Fujian province: a cross-sectional study

“… 20 Our recent research also showed Cervista A9 was a good primary screening strategy. 21 This study also suggested that simple species A9 infection was overwhelming in women with CIN2, CIN3 and cancer, and all the infection rates were higher than 50%. Therefore, species A9 could be used to triage patients who were HPV-positive but who without substantial abnormal cytology.…”

ASF1B promotes cervical cancer progression through stabilization of CDK9

“…Among these cases, approximately 90% occur in developing countries, and more than 50,000 females succumb to cervical cancer each year in China 5,6 . Our current understanding of cervical cancer is that persistent human papillomavirus (HPV) infection contributes to tumor establishment [7][8][9][10] . However, HPV infection alone is not sufficient for tumor development, and host genetic factors may also be involved in cervical cancer pathogenesis 11 .…”